证券代码：688710 证券简称：益诺思 公告编号：2025-034 上海益诺思生物技术股份有限公司 2025年第三次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 9 月 23 日 （二） 股东大会召开的地点：中国（上海）自由贸易试验区郭守敬路 199 号中 心报告厅 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 49 | | --- | --- | | 普通股股东人数 | 49 | | 2、出席会议的股东所持有的表决权数量 | 90,768,038 | | 普通股股东所持有表决权数量 | 90,768,038 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 64.3838 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 64.3838 ...

重大事项提示 2025 年 1-6 月，益诺思实现营业收入 37,522.86 万元，同比下降 38.04%； 实现归属于上市公司股东的净利润-1,518.95 万元，同比下降 115.88%；实现归属 于上市公司股东的扣除非经常性损益后的净利润-3,255.66 万元，同比下降 136.39%。主要系公司受国内医药行业投融资放缓和市场需求增长放缓的影响， 市场竞争加剧导致销售订单价格下降，毛利率同比下滑，利润空间被压缩。2025 年上半年，公司主营业务、核心竞争力、其他主要财务指标未发生重大不利变化； 所处行业不存在产能过剩、持续衰退或者技术替代等情形；持续经营能力不存在 重大风险。 国泰海通证券股份有限公司 关于上海益诺思生物技术股份有限公司 2025 年持续督导半年度跟踪报告 | 保荐机构名称：国泰海通证券股份有限公司 | 被保荐公司简称：益诺思 | | --- | --- | | 保荐代表人姓名：刘赛辉 陈轶超 | 被保荐公司代码：688710 | 经中国证券监督管理委员会《关于同意上海益诺思生物技术股份有限公司首 次公开发行股票注册的批复》（证监许可〔2024〕762 号）批复，上海益诺思生 物技术 ...

Company Overview - Full Name: Shanghai Yinuosi Biotechnology Co., Ltd [1] - Abbreviation: Yinuosi [1] - Stock Code: 688710.SH [1] - IPO Application Date: December 29, 2022 [1] - Listing Date: September 3, 2024 [1] - Listing Board: Shanghai Stock Exchange Sci-Tech Innovation Board [1] - Industry: Research and Experimental Development [1] - IPO Sponsor: Haitong Securities [1] - Lead Underwriters: Haitong Securities [1] - Legal Advisor: Guohao Law Firm (Shanghai) [1] - Audit Firm: Lixin Certified Public Accountants (Special General Partnership) [1] Disclosure and Evaluation - Disclosure Issues: The actual controller, China National Pharmaceutical Group, has inconsistencies in the main business of its subsidiary related to the issuer, requiring clarification on the completeness of similar business entities [1] - Regulatory Penalties: No penalties [2] - Public Supervision: No penalties [2] - Listing Cycle: Yinuosi's listing cycle is 614 days, shorter than the average of 629.45 days for A-share companies in 2024 [2] - Multiple Applications: Yinuosi is not categorized as having multiple applications [2] Financial Metrics - Issuance Costs: The underwriting and sponsorship fees amount to 44.4235 million yuan, with a commission rate of 6.61%, lower than the average of 7.71% [3] - First Day Performance: The stock price increased by 41.61% on the first day of listing [3] - Three-Month Performance: The stock price rose by 108.39% within three months of listing [4] - Issuance Price-Earnings Ratio: The issuance P/E ratio is 15.40 times, which is 83.83% of the industry average of 18.37 times [5] - Actual Fundraising: Expected fundraising is 1.664 billion yuan, but actual fundraising is only 672 million yuan, a decrease of 59.63% [6] Short-term Performance - Revenue Growth: In 2024, the company's revenue increased by 9.94% year-on-year [7] - Net Profit Decline: The net profit attributable to the parent company decreased by 24.00% year-on-year, and the non-recurring net profit dropped by 28.12% year-on-year [7] - Abandonment Rate: The abandonment rate is 0.23% [7] Overall Score - Total Score: Yinuosi's IPO project received a total score of 86, classified as B-level [7] - Negative Factors: The score is impacted by the need for improved disclosure quality, significant reduction in actual fundraising, decline in net profit in the first accounting year, and the abandonment rate of 0.23% [7]

两融数据显示，该股最新（9月18日）两融余额为7728.90万元，其中，融资余额为7728.90万元，近10日 减少1307.17万元，环比下降14.47%。 机构评级来看，近10日共有1家机构对该股进行评级，9月12日东方证券发布的研报给予公司目标价为 43.24元。 公司发布的半年报数据显示，上半年公司共实现营业收入3.75亿元，同比下降38.04%，实现净利 润-1518.95万元，同比下降115.88%，基本每股收益为-0.1100元。（数据宝）注：本文系新闻报道，不 构成投资建议，股市有风险，投资需谨慎。 （原标题：益诺思创历史新高，融资客减仓） 益诺思股价创出历史新高，截至10:09，该股上涨7.66%，股价报49.78元，成交量157.01万股，成交金额 7555.59万元，换手率1.73%，该股最新A股总市值达70.18亿元，该股A股流通市值45.15亿元。 证券时报•数据宝统计显示，益诺思所属的医药生物行业，目前整体跌幅为0.77%，行业内，目前股价上 涨的有60只，涨幅居前的有益诺思、首药控股、百诚医药等，涨幅分别为7.66%、5.20%、4.61%。股价 下跌的有428只，跌幅居前的有塞 ...

Market Overview - On September 17, the medical services sector rose by 0.02% compared to the previous trading day, with Yinos leading the gains [1] - The Shanghai Composite Index closed at 3876.34, up 0.37%, while the Shenzhen Component Index closed at 13215.46, up 1.16% [1] Top Gainers in Medical Services Sector - Yinos (688710) closed at 46.85, with an increase of 8.65% and a trading volume of 46,200 lots, amounting to a transaction value of 207 million [1] - New Mileage (002219) closed at 2.49, up 4.18%, with a trading volume of 2,568,500 lots and a transaction value of 638 million [1] - Prasis (301257) closed at 50.33, increasing by 3.52% with a trading volume of 50,700 lots, totaling 249 million [1] Top Losers in Medical Services Sector - Medisi (688202) closed at 76.00, down 5.41%, with a trading volume of 91,400 lots and a transaction value of 700 million [2] - Yaoshi Technology (300725) closed at 44.74, decreasing by 5.11%, with a trading volume of 262,900 lots and a transaction value of 1.18 billion [2] - Zhaoyan New Drug (603127) closed at 40.40, down 4.27%, with a trading volume of 444,300 lots and a transaction value of 1.806 billion [2] Fund Flow Analysis - On the same day, the medical services sector experienced a net outflow of 626 million from institutional investors, while retail investors saw a net inflow of 482 million [2] - The top stocks by net inflow from institutional investors included Yinos (688710) with a net inflow of 26.06 million, and New Mileage (002219) with 38.30 million [3] - Conversely, the top stocks with net outflow from institutional investors included Yao Ming Kande (603259) with a net outflow of 428 million [3]

Core Insights - Yinos Bio's stock price increased by 5.01% on September 17, reaching 45.28 CNY per share, with a trading volume of 1.21 billion CNY and a turnover rate of 3.06%, resulting in a total market capitalization of 6.384 billion CNY. The stock has risen for five consecutive days, with a cumulative increase of 14.8% during this period [1] Company Overview - Shanghai Yinos Biotechnology Co., Ltd. is located in the China (Shanghai) Pilot Free Trade Zone and was established on May 12, 2010. The company went public on September 3, 2024. Its main business involves providing comprehensive research and development services (CRO) focused on non-clinical research services in biomedicine [1] - The revenue composition of Yinos Bio is as follows: non-clinical services account for 96.31%, clinical services for 3.42%, and other services for 0.27% [1] Shareholder Information - Among Yinos Bio's top ten circulating shareholders, one fund from Harvest Fund Management, the Harvest Medical Health Stock A (005303), entered the top ten in the second quarter, holding 344,300 shares, which represents 1.22% of the circulating shares. The estimated floating profit today is approximately 743,700 CNY, with a total floating profit of 1.9145 million CNY during the five-day increase [2] - The Harvest Medical Health Stock A fund was established on December 4, 2017, with a current scale of 786 million CNY. Year-to-date returns are 46.61%, ranking 574 out of 4222 in its category; the one-year return is 62.24%, ranking 1519 out of 3804; and since inception, the return is 99.77% [2] Fund Manager Performance - The fund manager of Harvest Medical Health Stock A is Sun Xiaohui, who has been in the position for 160 days, managing assets totaling 985 million CNY, with the best fund return during this period being 41.81% and the worst being 41.31% [3] - Co-manager Hao Miao has been in the role for 6 years and 246 days, managing assets of 3.652 billion CNY, with the best fund return during this period being 183.83% and the worst being -27.96% [3]

Core Viewpoint - Yinos's stock price has shown significant growth this year, with a notable increase in recent trading days, indicating positive market sentiment towards the company [2]. Group 1: Stock Performance - Yinos's stock price increased by 25.04% year-to-date, with a 13.11% rise in the last five trading days, 5.09% in the last 20 days, and 36.90% over the last 60 days [2]. - As of September 17, Yinos's stock was trading at 44.00 CNY per share, with a market capitalization of 6.203 billion CNY [1]. Group 2: Financial Performance - For the first half of 2025, Yinos reported a revenue of 375 million CNY, a year-on-year decrease of 38.04%, and a net profit attributable to shareholders of -15.1895 million CNY, down 115.88% year-on-year [2]. - Cumulative cash dividends paid by Yinos since its A-share listing amount to 45.1135 million CNY [3]. Group 3: Shareholder Information - As of June 30, 2025, Yinos had 5,386 shareholders, a decrease of 0.90% from the previous period, with an average of 5,235 circulating shares per shareholder, an increase of 0.91% [2]. - Notable changes in institutional holdings include ICBC Medical Health Stock becoming the seventh largest shareholder, increasing its holdings by 72,300 shares, while new shareholders include ICBC Strategic Transformation Stock and Harvest Medical Health Stock [3].

Core Insights - The medical services sector experienced a slight increase of 0.29% on September 16, with Chengda Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3861.87, up 0.04%, while the Shenzhen Component Index closed at 13063.97, up 0.45% [1] Medical Services Sector Performance - Chengda Pharmaceutical (301201) closed at 33.32, with a significant increase of 15.25% and a trading volume of 157,100 shares, amounting to a transaction value of 508 million yuan [1] - Haocen Medical (002622) saw a rise of 10.10%, closing at 4.25 with a trading volume of 993,200 shares, totaling 409 million yuan [1] - Aoyang Health (002172) increased by 10.00%, closing at 4.73 with a trading volume of 87,500 shares, amounting to 41.39 million yuan [1] - Bid Pharma (688073) rose by 6.48%, closing at 74.73 with a trading volume of 26,000 shares, totaling 192 million yuan [1] - Yikang Biological (688046) increased by 5.56%, closing at 19.75 with a trading volume of 79,600 shares, amounting to 158 million yuan [1] - Other notable performers include Haoyuan Pharmaceutical (688131) with a 4.44% increase, closing at 78.28, and Xinlicheng (002219) with a 3.46% increase, closing at 2.39 [1] Fund Flow Analysis - The medical services sector saw a net outflow of 228 million yuan from institutional investors, while retail investors contributed a net inflow of 59.64 million yuan [3] - Speculative funds recorded a net inflow of 168 million yuan into the sector [3]

Core Points - The company is changing its official website and investor email domain to enhance its brand image [1] - The new website and email will be effective from September 15, 2025, with a transition period until March 15, 2026 [1] - During the transition, the old website will automatically redirect to the new one, and emails sent to the old investor email will be forwarded to the new one [1] - The company's investor contact number, fax, and address will remain unchanged [1]

证券代码：688710 证券简称：益诺思 上海益诺思生物技术股份有限公司 2025 年第三次临时股东大会会议资料 2025 年第三次临时股东大会会议资料目录 | 2025年第三次临时股东大会须知 | | 3 | | --- | --- | --- | | 2025年第三次临时股东大会会议议程 | | 5 | | 议案一：关于续聘会计师事务所的议案 | | 6 | | 议案二：关于购买董监高责任险的议案 | | 7 | 上海益诺思生物技术股份有限公司 2025 年第三次临时股东大会 会议资料 二〇二五年九月 七、股东发言由大会主持人组织，股东发言时应先报告所持股票数量和持 股人名称。股东在股东大会上的发言，应围绕本次大会所审议的议案，简明扼 要，时间原则上不超过 5 分钟，经主持人同意后方可延长发言时间。主持人可 安排公司董事、监事和其他高级管理人员等回答股东问题，与本次股东大会议 题无关或涉及国家秘密、公司商业秘密或可能损害公司、股东利益的问题，大 上海益诺思生物技术股份有限公司 2025 年第三次临时股东大会会议资料 2025年第三次临时股东大会须知 根据中国证券监督管理委员会《上市公司股东大会规则》和《公 ...